Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The following markers showed statistically significant increased mean concentrations in patients with SSc in comparison to healthy control: resistin (13.41 vs 8.54 ng/mL; P = 0.0012), endothelin-1 (1.99 vs 1.31 pg/mL; P = 0.0072) and fractalkine (2.93 vs 1.68 ng/mL; P = 0.0007).
|
31667578 |
2019 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Considering the role of endothelin-1 (ET-1) in tissue remodeling and fibrosis during the development of scleroderma as well as the effect of α-Klotho in pathogenesis of calcinosis and/or endothelial cell injury and its correlation with severity of disease, this study aimed to evaluate serum ET-1, α-Klotho and 25(OH) vitamin D levels in patients with limited and diffuse scleroderma compared to healthy subjects.
|
28831601 |
2017 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EMPs, s-Fractalkine and endothelin-1 were independent factors associated with SSc.
|
28320472 |
2017 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study identified endothelium dysfunction biomarkers (FMD and ET-1) and severe microvascular damage in NVC as strong predictors of new DU in SSc patients.
|
28128745 |
2017 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibodies against angiotensin II type I receptor (AT1R) and endothelin-1 type A receptor (ETAR) play important roles in the pathogenesis of SSc.
|
26970493 |
2016 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many previous studies have focused on the role of ET-1 in scleroderma (systemic sclerosis, SSc).
|
25990837 |
2016 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibroblasts isolated from healthy controls and SSc patients were treated with TGF-β and ET-1 and successively analyzed for alpha smooth muscle actin (α-SMA) and collagen (Col1A1) expression and for the Sma and Mad Related (SMAD) phosphorylation.
|
26357964 |
2015 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Like endothelin-1 (ET-1), U-II could play an important role in SSc pathogenesis.
|
22045841 |
2012 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with systemic sclerosis (SSc), the relationship between innate immune activation, represented by increased expression of interferon (IFN)-regulated genes, and vascular injury/activation, manifest by increased endothelin-1 (ET-1), endothelin converting enzyme-1 (ECE1) and intercellular adhesion molecule-1, is uncertain.
|
21068089 |
2011 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Endothelin-1 does not change the function of monocyte-derived dendritic cells grown from patients with systemic sclerosis.
|
18991099 |
2008 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
[Assessment of plasma endothelin level measurement in systemic sclerosis].
|
17291632 |
2007 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study we investigated the ratio of circulating nitric oxide to endothelin-1 in patients with both SSc and PAH, and determined whether polymorphisms in NOS2 (the nitric oxide synthase 2 gene) are associated with susceptibility to PAH.
|
16813666 |
2006 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study was undertaken to delineate the signal transduction pathways utilized by ET-1 and compare them with those adopted by proinflammatory cytokine interleukin-1beta (IL-1beta) in normal and scleroderma dermal fibroblasts.
|
16447227 |
2006 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been well confirmed that plasma endothelin-1, as a vasoconstrictive factor, is elevated in patients with SSc.
|
14632763 |
2003 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, reduced responsiveness to exogenous endothelin-1 in systemic sclerosis suggests that downstream pathways may have already been activated in vivo.
|
11231316 |
2001 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Microautoradiographic analysis after 125I-labeled ET-1 binding showed a two- to threefold increase in the expression of total ET-1 receptors in scleroderma lung tissue localized to the alveolar epithelium and the pulmonary interstitium which was composed of mainly fibroblastic cells with macrophages and some microvessels.
|
9284832 |
1997 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The findings indicate that the overproduction of ET-1 is a novel abnormal function in SSc fibroblasts, and that ET-1 induced by fibroblasts may play a role in the fibrosis and Raynaud's phenomenon of SSc.
|
7944634 |
1994 |